EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐ IFNα ‐2a as Treatment for Chronic Hepatitis Delta

Pietro Lampertico iD, Pavel O Bogomolov, Vladimir Chulanov, Tatiana Stepanova, Viacheslav Morozov, Lena Allweiss, Maura Dandri iD, Jürgen Burhenne, Antje Blank, Sandra Ciesek, Carina Elsner, Ulf Dittmer und 6 weitere

Liver International · 2025

DOI: 10.1111/liv.70008 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Liver International, 2025. Verfasst von Pietro Lampertico und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Interferon-alpha, Polyethylene Glycols, Antiviral Agents, Hepatitis D, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences Inc. (Foster City, CA, USA), MYR GmbH (Bad Homburg, Germany), Hepatera (Moscow, Russian Federation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up.

Methods

Ninety patients were enrolled into six arms of 15 each (A–F); 60 patients were included in the main randomisation (arms A–D), and 30 patients (arms E–F) were randomised to the extension phase: (A) Peg‐IFNα‐2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg‐IFNα‐2a 180 μg QW; (C) BLV 5 mg QD + Peg‐IFNα‐2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg‐IFNα‐2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD. The primary endpoint was undetectable HDV RNA at week (W)72.

Results

At W72, 53%, 27%, 7%, 7% and 33% of patients achieved undetectable HDV RNA in arms B, C, D, E and F, respectively, versus 0% in arm A. More arm B versus A patients had a > 1 log 10 IU/mL decline in or loss of hepatitis B surface antigen (HBsAg) at W72 ( p = 0.017), including four patients with loss of HBsAg. Bile acid elevations were dose‐dependent and reversible following the completion of BLV treatment.

Conclusions

BLV combined with Peg‐IFNα‐2a was well tolerated and resulted in high rates of HDV RNA undetectability off‐treatment. Trial Registration NCT02888106

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-alphaPolyethylene GlycolsAntiviral AgentsHepatitis D, ChronicPeptidesHumansMaleFemaleRecombinant ProteinsMiddle AgedAdultDrug Therapy, CombinationHepatitis Delta VirusViral LoadTreatment OutcomeTenofovirRNA, ViralNucleic AcidsPolymers

Stichwörter der Autor:innen

HDVHepcludexMyrcludex Bbulevirtideentry inhibitorpegylated interferon alfa

Substanzen

Interferon-alphapeginterferon alfa-2aPolyethylene GlycolsAntiviral AgentsRecombinant ProteinsREP 2139TenofovirPeptidesRNA, ViralNucleic Acids

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • CRC "A. M. And A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • State Budgetary Institution of Health Care of Moscow Region, Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky, Moscow, Moscow, Russian Federation.
  • National Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russian Federation.
  • Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Limited Liability Company "Clinic of Modern Medicine," Moscow, Moscow, Russian Federation.

ORCID-Profile: Pietro Lampertico, Maura Dandri, Dmitry Manuilov, Heiner Wedemeyer

Förderung

  • Gilead Sciences Inc. (Foster City, CA, USA)
  • MYR GmbH (Bad Homburg, Germany)
  • Hepatera (Moscow, Russian Federation)
  • German Center for Infection Research (DZIF; Braunschweig, Germany)
  • Deutsches Zentrum für Infektionsforschung

Zitieren

APA

Lampertico, P., Bogomolov, P. O., Chulanov, V., Stepanova, T., Morozov, V., Allweiss, L., Dandri, M., Burhenne, J., Blank, A., Ciesek, S., Elsner, C., Dittmer, U., An, Q., Manuilov, D., Da, B. L., Flaherty, J. F., Urban, S., & Wedemeyer, H. (2025). Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐ IFNα ‐2a as Treatment for Chronic Hepatitis Delta. Liver International. https://doi.org/10.1111/liv.70008

Vancouver

Lampertico P, Bogomolov PO, Chulanov V, Stepanova T, Morozov V, Allweiss L, et al. Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐ IFNα ‐2a as Treatment for Chronic Hepatitis Delta. Liver International. 2025. doi:10.1111/liv.70008

BibTeX
@article{Lampertico2025,
  author = {Lampertico, Pietro and Bogomolov, Pavel O and Chulanov, Vladimir and Stepanova, Tatiana and Morozov, Viacheslav and Allweiss, Lena and Dandri, Maura and Burhenne, Jürgen and Blank, Antje and Ciesek, Sandra and Elsner, Carina and Dittmer, Ulf and An, Qi and Manuilov, Dmitry and Da, Ben L and Flaherty, John F and Urban, Stephan and Wedemeyer, Heiner},
  title = {Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐ IFNα ‐2a as Treatment for Chronic Hepatitis Delta},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70008}
}
Kostenlos starten →